EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 121.3

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

1.76K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.66 (+1.30%)

USD 548.90B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.21 (+1.26%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.31 (+1.16%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.33 (+1.20%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.34 (+1.42%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+1.70 (+1.16%)

USD 103.20B
JARI:XETRA Amundi Index Solutions - Amund..

+0.45 (+1.01%)

USD 102.92B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.67 (+1.32%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.34 (+0.25%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.28 (+1.28%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.89% 83% B 81% B-
Dividend Return 0.25% 12% F 6% D-
Total Return 15.14% 83% B 81% B-
Trailing 12 Months  
Capital Gain 14.33% 66% D+ 67% D+
Dividend Return 0.49% 14% F 8% B-
Total Return 14.81% 67% D+ 67% D+
Trailing 5 Years  
Capital Gain 47.84% 70% C- 70% C-
Dividend Return 5.96% 63% D 36% F
Total Return 53.80% 74% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.11% 58% F 57% F
Dividend Return 6.99% 62% D 59% D-
Total Return N/A 48% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 8.18% 65% D 73% C
Risk Adjusted Return 85.45% 93% A 93% A
Market Capitalization 0.70B 73% C 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.